Postdoctoral Research Fellow - Pharmaceutical

Postdoctoral Research Fellow - Pharmaceutical

About Northeastern:
Founded in 1898, Northeastern is a global research university and a world leader in experiential learning. The same commitment to connecting with the world drives our use-inspired research enterprise. The university offers a comprehensive range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. Our campuses in Charlotte, N.C., San Francisco, Seattle, and Toronto are regional platforms for undergraduate and graduate learning and collaborative research. Northeastern pursues advanced research in security and materials at the Innovation Campus in Burlington, Massachusetts, and in coastal sustainability at the Marine Science Center in Nahant, Massachusetts.

About the Opportunity:
The Northeastern University Pharmaceutical Industry Fellowship Program provides a dynamic academic environment offering fellows the opportunity for a wide breadth of experiences:

• Develop teaching skills through participation in our Teaching and Learning Seminar series
• Facilitate small and large group didactic education in partnership with a faculty mentor
• Utilize a layered learning model in experiential education by co-precepting students on pharmacy practice experiences including Northeastern's unique co-op program
• Create, present, and publish scholarly research through collaborative industry and university relationships
• Engage with faculty who participate in various interdisciplinary graduate programs including biotechnology, nanomedicine, immunology, health informatics, and drug discovery
• Network with area residents and other Northeastern fellows via professional development programs, teaching seminars, and participation on fellowship committees

About Deciphera Pharmaceuticals:
Deciphera Pharmaceuticals is a commercial biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates in clinical studies, QINLOCK is Deciphera's first FDA-approved drug, a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK, an oral oncolytic, is also approved in Canada and Australia for the treatment of fourth-line GIST.

Deciphera (NASDAQ: DCPH) is a publicly traded company headquartered in Waltham, Massachusetts. Our state-of-the-art research facility is located in Lawrence, Kansas.

We offer an outstanding culture and opportunity for personal and professional growth based on our “PATHS” Core Values:

- Patients - places the importance of improving the lives of patients and their caregivers at the forefront of every day's work.

- Accountability - for our performance and the way we work with coworkers and other stakeholders.

- Transparency - in our intent and actions to both internal and external stakeholders.

- Honesty and Integrity - fosters trust and strives to deliver on our and the company's promises.

- Stewardship - values and uses wisely the resources and investments provided to the company.

Deciphera's Science and Pipeline:

Deciphera is developing novel small molecule drug candidates to improve the lives of cancer patients by addressing key mechanisms of tumor and drug resistance that limit the effectiveness of many cancer therapies. Our pipeline of drug candidates is designed to stop cancers from growing and spreading by inhibiting mutant forms or over expression of a family of enzymes called kinase. Enabled by our proprietary kinase switch control inhibitor drug discovery platform, we have developed kinase switch control inhibitors that interact at a molecular level in a way that is distinct from other kinase inhibitors and are designed to generate higher and more durable rates of response.

We have developed a diverse pipeline of differentiated, wholly owned, orally administered, oncology drug candidates that includes, among others, our recently approved product, QINLOCK (ripretinib), a broad-spectrum KIT and PDGFRa kinase switch control inhibitor is approved for the treatment of fourth-line GIST. Our follow-on study of ripretinib, the INTRIGUE study, is a pivotal Phase 3 trial in second-line GIST. We also have two additional clinical-stage programs for drug candidates DCC-3014 and rebastinib, both immune-oncology (or immunokinase) inhibitors, targeting the kinases CSF1R and TIE2 respectively. Two research-stage programs are in the pipeline as well.

Responsibilities:

Roles and Responsibilities

• Plan and develop medical information letters and scientific communication materials
• Compile data, feedback, and metrics on medical information activities to support medical insight generation
• Publications support by strategically identifying data gaps, developing, and executing publication plan
• Attend medical congresses to gather medical insights or support the medical booth
• Work with regulatory, compliance, and medical director to review medical and promotional materials for medical accuracy
• Support in the planning and execution of advisory boards
• Develop evidence dossiers for use by key healthcare decision makers
• Work with the Field Medical Affairs Team (MSL) to gain an understanding of key opinion leader engagement and territory management
• Assist with management of Expanded Access program (EAP), review of medical education grants proposals, congress planning, and Investigator-Sponsored Research Review Committees
• Gain insights into medical strategy - planning & execution

Qualifications:
Doctor of Pharmacy degree from an ACPE accredited institution, eligible for licensure as a pharmacist in the State of Massachusetts.


Preferred Qualifications:
Excellent oral and written communication, time management, and leadership skills, ability to work independently and take initiative on a variety of projects at Deciphera Pharmaceuticals and Northeastern.

Salary Grade:
10

Additional Information:
Applicants should submit the following APPLICATION MATERIALS by the priority deadline of November 15, 2020:

1. Curriculum vitae (CV), uploaded
2. Unofficial PharmD transcripts, uploaded
3. Cover letter, uploaded

Three formal letters of recommendation (LORs) sent directly from the letter writer to PharmDFellowships@northeastern.edu by December 4, 2020. LOR writers should include the candidate's name and fellowship program(s) in the subject line (e.g. Smith, John - Deciphera, GSK).

Address cover letter and three LORs to:
J. Andrew Orr-Skirvin, PharmD, BCOP
Clinical Professor, School of Pharmacy
Chair, Department of Pharmacy & Health System Sciences
Director of Pharmaceutical Industry Fellowship Program
360 Huntington Ave, 140TF R218
Boston, MA 02115

Northeastern University is an equal opportunity employer, seeking to recruit and support a broadly diverse community of faculty and staff. Northeastern values and celebrates diversity in all its forms and strives to foster an inclusive culture built on respect that affirms inter-group relations and builds cohesion.

All qualified applicants are encouraged to apply and will receive consideration for employment without regard to race, religion, color, national origin, age, sex, sexual orientation, disability status, or any other characteristic protected by applicable law.

To learn more about Northeastern University's commitment and support of diversity and inclusion, please see www.northeastern.edu/diversity.


To apply, visit https://careers.pageuppeople.com/879/cw/en-us/job/503890

jeid-861a3fba99f65249aa5ccfa7310a6a60